SynthesisBMC surgery2025
Enhanced recovery after gastrectomy: updated Meta-analysis of 27 randomized trials (2018-2025).
Synthesis in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhanced Recovery After Surgery (ERAS) and Surgical Site Infections (SSIs).Antibiotics (Basel, Switzerland) · 2026Review
- Visceral adiposity rather than BMI predicts overall survival after curative gastrectomy for gastric cancer: a retrospective cohort study with age-stratified analyses.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhanced recovery after surgery (ERAS) programs are increasingly applied in upper-GI surgery, yet evidence in gastrectomy remains evolving with minimally invasive and robotic techniques. We updated the randomized evidence base to re-estimate effects on recovery, complications, and costs.
methodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane CENTRAL (2018-2025) for parallel-group randomized controlled trials comparing full-pathway ERAS programs versus conventional care in adult patients undergoing gastrectomy for gastric cancer, in accordance with PRISMA for Abstracts guidance. Length of stay was the primary endpoint; secondary outcomes included time to gastrointestinal recovery, postoperative complications, readmission, mortality, and hospital costs. Random-effects meta-analysis was performed, and certainty of evidence was evaluated using GRADE.
resultsTwenty-seven trials (n = 3,274 patients) met eligibility criteria. ERAS significantly shortened length of stay and accelerated gastrointestinal recovery. Overall postoperative complications were numerically lower under ERAS and became statistically significant in prespecified sensitivity analyses excluding high-risk-of-bias or overlapping trials (risk ratio [RR] 0.73, 95% CI 0.56-0.96). Individual complications (pneumonia, surgical-site infection, anastomotic leak) and 30-day readmission did not show clear evidence of a difference. Mortality was rare in both groups. Certainty of evidence was generally low to moderate.
conclusionsERAS in gastrectomy for gastric cancer may accelerate postoperative recovery and reduce costs without increasing complications or readmission. Standardized protocols and reporting are needed to enhance reliability and facilitate wider adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.